Navigation Links
Novel First-in-Class Anti-Cancer Agent in Development by Niiki Pharma Shows Promising Phase I Results
Date:6/1/2011

HOBOKEN, N.J. and PHILADELPHIA, June 1, 2011 /PRNewswire/ -- Niiki Pharma announced today that it will present interim data from the ongoing Phase I clinical study for its lead product, NKP-1339, at the 2011 American Society for Clinical Oncology meeting in Chicago, IL. NKP-1339 is a novel transferrin targeted ruthenium based anti-cancer compound. The intracellular targets of NKP-1339 include GRP78, a key regulator of mis-folded protein processing. In preclinical studies, in vivo and in vitro activity has been demonstrated against multiple tumor types, including those resistant to other anti-cancer agents.

The NKP-1339 Phase I trial is a dose-ascending trial and determines the safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics of NKP-1339. A total of 16 patients with metastatic solid tumors resistant to standard therapies have been treated to date at six different dose levels. NKP-1339 treatment has been generally well tolerated, with the most common drug related side effects of grade 1-2 fever and mild flu-like symptoms. MTD has not been reached and NKP-1339 dose escalation continues. Signs of anti-tumor activity (stable disease greater than or equal to four months; tumor regression) have been observed. A patient with a neuroendocrine tumor (NET) of the small intestine has been on NKP-1339 therapy for over 13 months with a continuing minor response. The patient remains on NKP-1339 therapy. Another patient with the metastatic gastrinoma NET exhibited six months stable disease, and two patients with metastatic non-small cell lung cancer exhibited four months stable disease.

The NKP-1339 Phase I trial is being led by Dr. Daniel Von Hoff, Translational Genomics Institute, Arizona, and Dr. Howard Burris, Sarah Canon Research Institute, Tennessee. Reflecting on NKP-1339's novel mechanism of action, Dr. Von Hoff noted "Resistance to anti-cancer therapy remains a major challenge in treatment of patients with metastatic cancer. First-
'/>"/>

SOURCE Niiki Pharma Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
2. Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
3. Novel Device Shows Promise for Reducing HIV Among Men
4. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
5. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
6. International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter
7. MonoSol Rx and KemPharm to Develop Novel PharmFilm® Product for ADHD
8. Amira Pharmaceuticals Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
9. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
10. Theramed Secures Exclusive Canadian Distribution Rights for Two Novel Obstetrics Products from Glenveigh
11. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED ... financial results for the second fiscal quarter ended September 30, 2011 ("2Q ... 1and Six M onths Ended ... Three   Months   EndedSeptember   ...
... LOUIS, Nov. 17, 2011 United Seating & Mobility (USM) ... transaction with The Rehab Specialist (TRS) to acquire and merge ... the Raleigh/Durham area. "The addition of Dana Mazer, ... growth market for USM and supports our regional initiative in ...
Cached Medicine Technology:China Medical Technologies Reports Second Fiscal Quarter Financial Results 2China Medical Technologies Reports Second Fiscal Quarter Financial Results 3China Medical Technologies Reports Second Fiscal Quarter Financial Results 4China Medical Technologies Reports Second Fiscal Quarter Financial Results 5China Medical Technologies Reports Second Fiscal Quarter Financial Results 6China Medical Technologies Reports Second Fiscal Quarter Financial Results 7China Medical Technologies Reports Second Fiscal Quarter Financial Results 8China Medical Technologies Reports Second Fiscal Quarter Financial Results 9China Medical Technologies Reports Second Fiscal Quarter Financial Results 10China Medical Technologies Reports Second Fiscal Quarter Financial Results 11China Medical Technologies Reports Second Fiscal Quarter Financial Results 12China Medical Technologies Reports Second Fiscal Quarter Financial Results 13China Medical Technologies Reports Second Fiscal Quarter Financial Results 14China Medical Technologies Reports Second Fiscal Quarter Financial Results 15China Medical Technologies Reports Second Fiscal Quarter Financial Results 16China Medical Technologies Reports Second Fiscal Quarter Financial Results 17China Medical Technologies Reports Second Fiscal Quarter Financial Results 18China Medical Technologies Reports Second Fiscal Quarter Financial Results 19China Medical Technologies Reports Second Fiscal Quarter Financial Results 20China Medical Technologies Reports Second Fiscal Quarter Financial Results 21China Medical Technologies Reports Second Fiscal Quarter Financial Results 22China Medical Technologies Reports Second Fiscal Quarter Financial Results 23China Medical Technologies Reports Second Fiscal Quarter Financial Results 24
(Date:12/26/2014)... Cooking and warming equipment ... 5. This score reflects slightly positive negotiation conditions for ... low switching costs and a low level of price ... availability of substitutes for cooking and warming equipment and ... aluminum, key inputs in the production process of this ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the Best ... 2014. The awards program, created in 2000, is one ... the country. The program is a public/private partnership between ... Economic Development, the Pennsylvania State Council of the Society ... Journal. , Charlie Wilson, Vice President of ...
(Date:12/25/2014)... 2014 The microscopy market is ... to reach $5,756.0 million by 2019. Optical microscopy ... The electron microscopes product segment is expected to ... , Rising focus on nanotechnology, technological advancements, and ... microscopy market. , Get Full Copy of Report ...
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... have discovered a new gene mutation they say causes ... Swiss family with Parkinson,s disease, using advanced DNA sequencing technology. ... of Human Genetics , was led by neuroscientists at the ... U.S., Canada, Europe, United Kingdom, Asia and the Middle East. ...
... July 15 (HealthDay News) -- After undergoing the weight-loss ... routine can help patients continue to lose weight and ... didn,t know until now whether morbidly obese bariatric surgery ... Dr. Abhimanyu Garg, chief of nutrition and metabolic diseases ...
... , FRIDAY, July 15 (HealthDay News) -- Injection drug ... regardless of what types of drugs they use, according ... users suffer higher rates of abuse, dependence and other ... help treatment programs specialize their care to target these ...
... for Medical Systems Biology (BIMSB) of the Max Delbrck ... be the first academic research institution in Continental Europe ... of single DNA molecules in real time. The SMRT ... high-throughput technologies. The researchers of the BIMSB will use ...
... HealthDay Reporter , THURSDAY, July 14 (HealthDay News) -- ... include smoking has dropped for the fifth year in a row, ... 72 percent drop since 2005 in smoking images in movies rated ... to 595 in 2010. In addition, the average number of smoking ...
... By Alan Mozes HealthDay Reporter , THURSDAY, July ... virus responsible for many well-known illnesses in humans and animals ... in another, according to researchers. This "jumping" virus is ... pneumonia and many other illnesses in humans. Until now -- ...
Cached Medicine News:Health News:Mayo researchers: Genetic mutation linked to Parkinson's disease 2Health News:Rigorous Exercise May Boost Benefits of Weight-Loss Surgery 2Health News:Injection Drug Users Most in Need of Treatment, Study Says 2Health News:Novel DNA sequencer for MDC's systems biology 2Health News:Less Lighting Up in Movies Aimed at Kids 2Health News:Less Lighting Up in Movies Aimed at Kids 3Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 2Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 3Health News:Novel Virus 'Jumped' From Monkeys to Humans, Researchers Find 4
... Continuous centralized monitoring with wireless connectivity, ... feature for the S/5 monitoring system that ... Monitor and S/5 FM to the S/5 ... ,Wireless operation is a flexible way of ...
... for anesthesia., ,The S/5 Anesthesia Monitor (AM) ... and upgradeable solution for routine to the most ... parameter modules, you can choose the set of ... And when your needs evolve, the modularity of ...
... in the operating and recovery room, ... for combined haemodynamic and airway gas monitoring ... anesthesia care units. The Cardiocap II is ... the basic haemodynamic measurements. Two of the ...
Anesthetists Precordial Kit incudes one set of 4 chromed plated chest pieces, a reusable monoscope of your choice, and 20 precordial adhesive discs....
Medicine Products: